Differences in the Recurrence and Mortality Outcomes Rates of Incidental and Nonincidental Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis of 21 329 Person-Years of Follow-up
Context:There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment.Objectives:To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTM...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 99; no. 8; pp. 2834 - 2843 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Bethesda, MD
Oxford University Press
01.08.2014
Copyright by The Endocrine Society Endocrine Society |
Subjects | |
Online Access | Get full text |
ISSN | 0021-972X 1945-7197 1945-7197 |
DOI | 10.1210/jc.2013-2118 |
Cover
Abstract | Context:There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment.Objectives:To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC.Setting and Design:Two reviewers performed searches of online databases (1966–2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria.Results:Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3–6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6–8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0–1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5–11%), with an OR of recurrence of 14.7 (95% CI, 5.6–54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence.Conclusions:Our meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC. |
---|---|
AbstractList | CONTEXT:There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment.
OBJECTIVES:To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC.
SETTING AND DESIGN:Two reviewers performed searches of online databases (1966–2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria.
RESULTS:Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3–6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6–8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0–1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5–11%), with an OR of recurrence of 14.7 (95% CI, 5.6–54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence.
CONCLUSIONS:Our meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC. Context:There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment.Objectives:To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC.Setting and Design:Two reviewers performed searches of online databases (1966–2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria.Results:Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3–6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6–8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0–1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5–11%), with an OR of recurrence of 14.7 (95% CI, 5.6–54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence.Conclusions:Our meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC. There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment. To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC. Two reviewers performed searches of online databases (1966-2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria. Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3-6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6-8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0-1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5-11%), with an OR of recurrence of 14.7 (95% CI, 5.6-54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence. Our meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC. There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment.CONTEXTThere is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment.To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC.OBJECTIVESTo compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC.Two reviewers performed searches of online databases (1966-2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria.SETTING AND DESIGNTwo reviewers performed searches of online databases (1966-2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria.Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3-6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6-8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0-1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5-11%), with an OR of recurrence of 14.7 (95% CI, 5.6-54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence.RESULTSOf 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3-6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6-8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0-1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5-11%), with an OR of recurrence of 14.7 (95% CI, 5.6-54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence.Our meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC.CONCLUSIONSOur meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC. |
Author | Boelaert, Kristien Al-maqbili, Taleb Campain, Nicholas Carter, Ben Martin, Emma Franklyn, Jayne A. Watkinson, John Mehanna, Hisham McCabe, Chris |
AuthorAffiliation | Institute of Head and Neck Studies and Education, School of Cancer Sciences (H.M., T.A., N.C.), University of Birmingham, Birmingham B15 2TT, United Kingdom; Cancer Research Clinical Trials Unit, School of Cancer Sciences (B.C., E.M.), University of Birmingham, Birmingham B15 2TT, United Kingdom; University Hospitals Birmingham NHS Foundation Trust (J.W.), University of Birmingham, Birmingham B15 2TT, United Kingdom; and School of Clinical and Experimental Medicine (C.M., K.B., J.A.F.), University of Birmingham, Birmingham B15 2TT, United Kingdom |
AuthorAffiliation_xml | – name: Institute of Head and Neck Studies and Education, School of Cancer Sciences (H.M., T.A., N.C.), University of Birmingham, Birmingham B15 2TT, United Kingdom; Cancer Research Clinical Trials Unit, School of Cancer Sciences (B.C., E.M.), University of Birmingham, Birmingham B15 2TT, United Kingdom; University Hospitals Birmingham NHS Foundation Trust (J.W.), University of Birmingham, Birmingham B15 2TT, United Kingdom; and School of Clinical and Experimental Medicine (C.M., K.B., J.A.F.), University of Birmingham, Birmingham B15 2TT, United Kingdom |
Author_xml | – sequence: 1 givenname: Hisham surname: Mehanna fullname: Mehanna, Hisham email: h.mehanna@bham.ac.uk organization: 1Institute of Head and Neck Studies and Education, School of Cancer Sciences (H.M., T.A., N.C.), University of Birmingham, Birmingham B15 2TT, United Kingdom – sequence: 2 givenname: Taleb surname: Al-maqbili fullname: Al-maqbili, Taleb organization: 1Institute of Head and Neck Studies and Education, School of Cancer Sciences (H.M., T.A., N.C.), University of Birmingham, Birmingham B15 2TT, United Kingdom – sequence: 3 givenname: Ben surname: Carter fullname: Carter, Ben organization: 2Cancer Research Clinical Trials Unit, School of Cancer Sciences (B.C., E.M.), University of Birmingham, Birmingham B15 2TT, United Kingdom – sequence: 4 givenname: Emma surname: Martin fullname: Martin, Emma organization: 2Cancer Research Clinical Trials Unit, School of Cancer Sciences (B.C., E.M.), University of Birmingham, Birmingham B15 2TT, United Kingdom – sequence: 5 givenname: Nicholas surname: Campain fullname: Campain, Nicholas organization: 1Institute of Head and Neck Studies and Education, School of Cancer Sciences (H.M., T.A., N.C.), University of Birmingham, Birmingham B15 2TT, United Kingdom – sequence: 6 givenname: John surname: Watkinson fullname: Watkinson, John organization: 3University Hospitals Birmingham NHS Foundation Trust (J.W.), University of Birmingham, Birmingham B15 2TT, United Kingdom – sequence: 7 givenname: Chris surname: McCabe fullname: McCabe, Chris organization: 4School of Clinical and Experimental Medicine (C.M., K.B., J.A.F.), University of Birmingham, Birmingham B15 2TT, United Kingdom – sequence: 8 givenname: Kristien surname: Boelaert fullname: Boelaert, Kristien organization: 4School of Clinical and Experimental Medicine (C.M., K.B., J.A.F.), University of Birmingham, Birmingham B15 2TT, United Kingdom – sequence: 9 givenname: Jayne A. surname: Franklyn fullname: Franklyn, Jayne A. organization: 4School of Clinical and Experimental Medicine (C.M., K.B., J.A.F.), University of Birmingham, Birmingham B15 2TT, United Kingdom |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28919678$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24828487$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kt9vFCEQxzemxl6rbz4bEmP0wa0Myy67fbtUq02qbWpN9IlwwOY4WTiB9XL_oH-X3I-mSZOSAGH4zAzzZY6KA-edLoqXgE-AAP6wkCcEQ1USgPZJMYGO1iWDjh0UE4wJlB0jPw-LoxgXGAOldfWsOCS0JS1t2aT499H0vQ7aSR2RcSjNNbrRcgxbExJOoa8-JGFNWqOrMUk_ZPBGpLz6Hl04aZR2-X6LfvPO3FuuxdJYK8Ia3c7XwZscysjgpQjSOD-IUzRF39cx6UEkI3Pav0avdil1EuXUCbuOZpuHAKpIh651iN6Vv7QIW_O5t9avynH5vHjaCxv1i_1-XPw4_3R79qW8vPp8cTa9LCXtCC77GjM161qpGo3pTAFjALpuVCNU39UgAQvWNF1VtQ10lSJMqBmDWSNBtErh6rh4t4u7DP7PqGPig4lS5yqd9mPkUNekYnXLmoy-foAu_BhyTZFX0FDKCKZtpl7tqXE2aMWXwQxZMX73Qxl4swdElML2QWSB4z3XdtA1bBOI7LiscIxB91yalHX1LgVhLAfMN-3CF5Jv2oVv2iU7vX_gdBf3EZzu8JW3KX_FbzuudOBzLWyac5wHzU8pswPFbT6VeVYb0d7u3Py4fCzBtn2r_6-h3HQ |
CODEN | JCEMAZ |
CitedBy_id | crossref_primary_10_18027_2224_5057_2024_008 crossref_primary_10_1245_s10434_015_4546_8 crossref_primary_10_1002_jso_25670 crossref_primary_10_1097_MD_0000000000006240 crossref_primary_10_1111_ajco_14070 crossref_primary_10_1007_s00405_024_09141_7 crossref_primary_10_3389_fonc_2022_856021 crossref_primary_10_3389_fmed_2022_906648 crossref_primary_10_9738_INTSURG_D_19_00020_1 crossref_primary_10_1097_MD_0000000000021996 crossref_primary_10_1055_s_0040_1722253 crossref_primary_10_1001_jamaoto_2022_3686 crossref_primary_10_7759_cureus_49563 crossref_primary_10_1007_s00423_015_1286_y crossref_primary_10_1155_2019_8579828 crossref_primary_10_3413_Nukmed_0792_16_01 crossref_primary_10_1016_j_surg_2021_06_027 crossref_primary_10_1055_a_1783_8154 crossref_primary_10_1007_s00405_020_05787_1 crossref_primary_10_1007_s12105_019_01124_z crossref_primary_10_1097_MOO_0000000000000142 crossref_primary_10_1016_j_rpedm_2016_04_003 crossref_primary_10_1016_j_anndiagpath_2020_151592 crossref_primary_10_3892_ol_2016_4640 crossref_primary_10_20945_2359_3997000000013 crossref_primary_10_1089_thy_2020_0845 crossref_primary_10_1016_j_endonu_2016_05_009 crossref_primary_10_1245_s10434_019_07587_2 crossref_primary_10_20945_2359_3997000000537 crossref_primary_10_1016_j_ejso_2022_04_001 crossref_primary_10_1186_s12885_018_4296_7 crossref_primary_10_3389_fendo_2020_571421 crossref_primary_10_1111_1759_7714_12858 crossref_primary_10_1016_j_suronc_2015_04_005 crossref_primary_10_3803_EnM_2024_1937 crossref_primary_10_1007_s11154_023_09844_y crossref_primary_10_1007_s12020_023_03321_x crossref_primary_10_1038_modpathol_2015_92 crossref_primary_10_3389_fonc_2021_644645 crossref_primary_10_1016_j_acra_2023_11_030 crossref_primary_10_1016_j_endoen_2016_10_008 crossref_primary_10_1055_a_2032_5810 crossref_primary_10_1111_cyt_12586 crossref_primary_10_1097_RCT_0000000000000883 crossref_primary_10_1186_s12957_017_1130_7 crossref_primary_10_16919_bozoktip_524623 crossref_primary_10_2174_1566524019666190717161359 crossref_primary_10_1089_thy_2015_0101 crossref_primary_10_1507_endocrj_EJ20_0692 crossref_primary_10_1016_j_jprot_2019_103414 crossref_primary_10_3390_cancers12051345 crossref_primary_10_1186_s13044_023_00148_6 crossref_primary_10_26779_2522_1396_2020_3_4_91 crossref_primary_10_36290_vnl_2017_115 crossref_primary_10_1007_s00464_019_06762_6 crossref_primary_10_1097_MD_0000000000005067 crossref_primary_10_1186_s13104_016_2018_2 crossref_primary_10_3389_fendo_2018_00736 crossref_primary_10_1016_j_surg_2021_05_016 crossref_primary_10_20945_2359_4292_2023_0371 crossref_primary_10_3389_fonc_2024_1354288 crossref_primary_10_5041_RMMJ_10467 crossref_primary_10_1007_s40618_020_01342_1 crossref_primary_10_1016_j_canep_2019_03_011 crossref_primary_10_1016_S2213_8587_16_30180_2 crossref_primary_10_3390_ijms18061292 crossref_primary_10_1002_jcb_25506 crossref_primary_10_1055_a_2008_0824 crossref_primary_10_1089_thy_2019_0328 crossref_primary_10_1308_rcsann_2022_0094 crossref_primary_10_1016_S0003_4266_16_30008_7 crossref_primary_10_1016_j_humpath_2017_05_013 crossref_primary_10_5306_wjco_v11_i6_320 crossref_primary_10_1016_j_ejso_2016_07_002 crossref_primary_10_1089_thy_2016_0247 crossref_primary_10_1089_thy_2017_0250 crossref_primary_10_16956_kjes_2017_17_1_1 crossref_primary_10_1038_s41417_024_00854_9 crossref_primary_10_20945_2359_3997000000341 crossref_primary_10_3389_fendo_2023_1112506 crossref_primary_10_1002_cncr_29689 crossref_primary_10_1016_j_endien_2019_09_003 crossref_primary_10_1007_s12020_023_03564_8 crossref_primary_10_1089_thy_2016_0238 crossref_primary_10_1007_s12020_024_03907_z crossref_primary_10_1002_uog_20389 crossref_primary_10_1089_thy_2021_0151 crossref_primary_10_1136_bmjpo_2022_001810 crossref_primary_10_1007_s12022_018_9546_3 crossref_primary_10_4158_EP161497_OR crossref_primary_10_3389_fendo_2023_1256209 crossref_primary_10_1007_s12020_024_03861_w crossref_primary_10_1016_j_bjorl_2020_05_004 crossref_primary_10_12998_wjcc_v8_i8_1350 crossref_primary_10_14366_usg_15027 crossref_primary_10_23736_S2724_6507_20_03283_6 crossref_primary_10_1016_j_cca_2014_10_035 crossref_primary_10_3389_fendo_2021_666315 crossref_primary_10_4103_jhnps_jhnps_44_23 crossref_primary_10_3389_fendo_2023_1108125 crossref_primary_10_1089_thy_2015_0375 crossref_primary_10_1016_j_endinu_2019_09_012 crossref_primary_10_1007_s40618_020_01326_1 crossref_primary_10_1530_EJE_15_1223 crossref_primary_10_1530_EJE_17_0160 crossref_primary_10_1038_nrdp_2015_77 crossref_primary_10_1016_j_jss_2022_04_018 crossref_primary_10_1186_s12957_018_1501_8 crossref_primary_10_1016_j_amjsurg_2023_11_003 crossref_primary_10_1155_2022_8108256 crossref_primary_10_1177_00369330211032352 crossref_primary_10_3390_jcm11174975 crossref_primary_10_2147_CMAR_S308012 crossref_primary_10_1055_a_2318_5320 crossref_primary_10_20945_2359_4292_2022_0506 crossref_primary_10_14639_0392_100X_N1412 crossref_primary_10_1507_endocrj_EJ21_0073 crossref_primary_10_2967_jnumed_117_191338 crossref_primary_10_1016_j_suronc_2018_03_004 crossref_primary_10_1016_j_surg_2019_05_078 crossref_primary_10_1016_j_ejso_2015_10_011 crossref_primary_10_1093_ajcp_aqx051 crossref_primary_10_1016_j_jpeds_2020_07_013 crossref_primary_10_1016_j_jmu_2015_02_005 crossref_primary_10_3390_jcm10163569 crossref_primary_10_3390_jcm11154613 crossref_primary_10_1007_s12020_023_03510_8 crossref_primary_10_1097_MD_0000000000016386 crossref_primary_10_1089_thy_2018_0391 crossref_primary_10_1530_ERC_16_0396 crossref_primary_10_3390_jcm11164929 crossref_primary_10_1002_dc_24117 crossref_primary_10_1007_s12020_023_03533_1 crossref_primary_10_1089_thy_2015_0391 |
Cites_doi | 10.1186/1756-6614-1-8 10.1111/j.1365-2265.2008.03366.x 10.1089/thy.2009.0110 10.1002/cncr.24416 10.1245/s10434-008-9958-2 10.1002/cncr.26425 10.1530/EJE-12-0105 10.1002/sim.1187 10.1210/jc.2003-031982 10.4103/0022-3859.30323 10.1002/jso.20746 10.1507/endocrj.46.209 10.1002/1097-0142(19900301)65:5<1173::AID-CNCR2820650524>3.0.CO;2-2 10.1210/jc.2005-2372 10.1097/SLA.0b013e318230036d 10.1007/s00268-005-0363-8 10.1210/jc.2011-1546 10.3109/0284186X.2012.723822 10.1007/s00268-009-0359-x 10.1002/hed.21517 10.1245/s10434-009-0332-9 10.1089/thy.2008.0185 10.1007/s00268-009-0303-0 10.1177/000313481007600313 10.1258/000456306775141623 10.1097/01.SLA.0000055273.58908.19 10.1160/nukmed-0059 10.1245/s10434-011-1556-z 10.1148/radiol.2373050220 10.1111/j.1749-4486.2010.02085.x 10.1007/s00268-008-9870-8 10.1001/jama.295.18.2164 10.1016/0197-2456(86)90046-2 10.1089/thy.2008.0270 10.1210/jcem.87.4.8352 10.1210/jc.2012-1465 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3 10.1007/s00268-007-9131-2 10.1097/00006231-200501000-00002 10.1007/s00268-009-0375-x 10.1007/s00423-007-0213-2 |
ContentType | Journal Article |
Copyright | Copyright © 2014 by the Endocrine Society 2014 Copyright © 2014 by The Endocrine Society 2015 INIST-CNRS Copyright © 2014 by the Endocrine Society |
Copyright_xml | – notice: Copyright © 2014 by the Endocrine Society 2014 – notice: Copyright © 2014 by The Endocrine Society – notice: 2015 INIST-CNRS – notice: Copyright © 2014 by the Endocrine Society |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 |
DOI | 10.1210/jc.2013-2118 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-7197 |
EndPage | 2843 |
ExternalDocumentID | 24828487 28919678 10_1210_jc_2013_2118 00004678-201408000-00030 10.1210/jc.2013-2118 |
Genre | Meta-Analysis Systematic Review Journal Article |
GrantInformation_xml | – fundername: Medical Research Council grantid: G0601811 |
GroupedDBID | --- -~X .55 .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 4.4 48X 53G 5GY 5RS 5YH 8F7 AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABBLC ABDFA ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ACGFO ACGFS ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK AELWJ AEMDU AENEX AENZO AETBJ AEWNT AFCHL AFFZL AFGWE AFOFC AFRAH AFXAL AGINJ AGKRT AGQXC AGUTN AHMBA AHMMS AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BSWAC BTRTY C45 CDBKE CS3 D-I DAKXR DIK E3Z EBS EJD EMOBN ENERS F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 HZ~ H~9 KBUDW KOP KQ8 KSI KSN L7B M5~ MHKGH MJL N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G REU ROX ROZ TEORI TJX TLC TR2 TWZ VVN W8F WOQ X7M YBU YFH YHG YOC YSK ZY1 ~02 ~H1 .GJ 3O- 7X7 88E 8FI 8FJ AAJQQ AAKAS AAPGJ AAQQT AAUQX AAWDT AAYJJ ABDPE ABUWG ABXZS ACFRR ACVCV ACZBC ADMTO ADNBA ADZCM AEMQT AEOTA AERZD AFFNX AFFQV AFKRA AFYAG AGMDO AGORE AHGBF AI. AJBYB AJDVS ALXQX APJGH AQDSO AQKUS AVNTJ BENPR BPHCQ BVXVI CCPQU EIHJH FEDTE FYUFA HMCUK HVGLF IAO IHR INH ITC J5H M1P MBLQV N4W NU- OBFPC PHGZM PHGZT PQQKQ PROAC PSQYO TMA UKHRP VH1 WHG X52 ZGI ZXP AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM PJZUB PPXIY 7QP 7T5 7TM H94 K9. 7X8 |
ID | FETCH-LOGICAL-c4920-f507db98cd6e04bd17711e56d6adf951c10a76693386193d27adb71b6c1a8dd03 |
ISSN | 0021-972X 1945-7197 |
IngestDate | Mon Sep 08 06:43:45 EDT 2025 Mon Jun 30 12:44:24 EDT 2025 Wed Jul 30 01:46:37 EDT 2025 Wed Apr 02 07:18:34 EDT 2025 Thu Apr 24 23:01:59 EDT 2025 Tue Jul 01 01:10:31 EDT 2025 Fri May 16 03:44:10 EDT 2025 Fri Feb 07 10:35:30 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Endocrinopathy Obesity Relapse Prognosis Nutrition Mortality Rate Thyroid diseases Nutrition disorder Metabolic diseases Systematic review Malignant tumor Epidemiology Thyroid carcinoma Metaanalysis Surveillance Evolution Endocrinology Nutritional status Comparative study Cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4920-f507db98cd6e04bd17711e56d6adf951c10a76693386193d27adb71b6c1a8dd03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
PMID | 24828487 |
PQID | 3164472048 |
PQPubID | 2046206 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1552375876 proquest_journals_3164472048 pubmed_primary_24828487 pascalfrancis_primary_28919678 crossref_citationtrail_10_1210_jc_2013_2118 crossref_primary_10_1210_jc_2013_2118 wolterskluwer_health_00004678-201408000-00030 oup_primary_10_1210_jc_2013-2118 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-August |
PublicationDateYYYYMMDD | 2014-08-01 |
PublicationDate_xml | – month: 08 year: 2014 text: 2014-August |
PublicationDecade | 2010 |
PublicationPlace | Bethesda, MD |
PublicationPlace_xml | – name: Bethesda, MD – name: United States – name: Washington |
PublicationTitle | The journal of clinical endocrinology and metabolism |
PublicationTitleAlternate | J Clin Endocrinol Metab |
PublicationYear | 2014 |
Publisher | Oxford University Press Copyright by The Endocrine Society Endocrine Society |
Publisher_xml | – name: Oxford University Press – name: Copyright by The Endocrine Society – name: Endocrine Society |
References | Pelttari ( key 2019041113340591700_B28) 2009; 70 Yamamoto ( key 2019041113340591700_B35) 1990; 65 Pellegriti ( key 2019041113340591700_B15) 2004; 89 DerSimonian ( key 2019041113340591700_B21) 1986; 7 Harach ( key 2019041113340591700_B34) 1985; 56 Mercante ( key 2019041113340591700_B22) 2009; 19 Gul ( key 2019041113340591700_B10) 2009; 13 Buffet ( key 2019041113340591700_B31) 2012; 167 Davies ( key 2019041113340591700_B3) 2006; 295 Blondeau ( key 2019041113340591700_B18) 1992; 176 Lo ( key 2019041113340591700_B7) 2006; 30 Lin ( key 2019041113340591700_B13) 2008; 15 Xu ( key 2019041113340591700_B43) 2010; 31 Abboud ( key 2019041113340591700_B47) 2010; 76 Lombardi ( key 2019041113340591700_B11) 2010; 34 Roti ( key 2019041113340591700_B38) 2006; 91 Hedinger ( key 2019041113340591700_B1) 1988 Gülben ( key 2019041113340591700_B46) 2008; 393 Moon ( key 2019041113340591700_B48) 2011; 18 Besic ( key 2019041113340591700_B41) 2009; 16 Giordano ( key 2019041113340591700_B9) 2010; 35 Arora ( key 2019041113340591700_B16) 2009; 19 Friguglietti ( key 2019041113340591700_B30) 2011; 33 Schönberger ( key 2019041113340591700_B39) 2007; 46 Chen ( key 2019041113340591700_B2) 2009; 115 Yu ( key 2019041113340591700_B23) 2011; 254 Cappelli ( key 2019041113340591700_B26) 2007; 95 Khoo ( key 2019041113340591700_B32) 2002; 87 Ito ( key 2019041113340591700_B12) 2007; 31 Zhang ( key 2019041113340591700_B24) 2012; 97 Frates ( key 2019041113340591700_B5) 2005; 237 Cooper ( key 2019041113340591700_B6) 2009; 19 key 2019041113340591700_B20 Wada ( key 2019041113340591700_B37) 2003; 237 Ito ( key 2019041113340591700_B36) 2010; 34 Pisanu ( key 2019041113340591700_B42) 2009; 33 Sugitani ( key 2019041113340591700_B8) 1999; 46 Reynolds ( key 2019041113340591700_B19) 2006; 43 key 2019041113340591700_B27 Carlini ( key 2019041113340591700_B14) 2005; 24 Roerink ( key 2019041113340591700_B29) 2013; 52 Niemeier ( key 2019041113340591700_B33) 2012; 118 Wartofsky ( key 2019041113340591700_B4) 2012; 97 Sakorafas ( key 2019041113340591700_B45) 2007; 53 Pazaitou-Panayiotou ( key 2019041113340591700_B40) 2008; 1 Thompson ( key 2019041113340591700_B25) 2002; 21 Dietlein ( key 2019041113340591700_B44) 2005; 26 Sugitani ( key 2019041113340591700_B17) 2010; 34 |
References_xml | – volume: 31 start-page: 205 issue: 5 year: 2010 ident: key 2019041113340591700_B43 article-title: Surgical treatment of incidental and non-incidental papillary thyroid microcarcinoma publication-title: G Chir – volume: 1 start-page: 8 issue: 1 year: 2008 ident: key 2019041113340591700_B40 article-title: Cervical masses as manifestation of papillary thyroid carcinomas </ = 10 mm in diameter, in patients with unknown thyroid disease publication-title: Thyroid Res doi: 10.1186/1756-6614-1-8 – volume: 70 start-page: 493 issue: 3 year: 2009 ident: key 2019041113340591700_B28 article-title: Health-related quality of life in long-term follow-up of patients with cured TNM Stage I or II differentiated thyroid carcinoma publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2008.03366.x – volume: 19 start-page: 1167 issue: 11 year: 2009 ident: key 2019041113340591700_B6 article-title: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer publication-title: Thyroid doi: 10.1089/thy.2009.0110 – volume: 115 start-page: 3801 issue: 16 year: 2009 ident: key 2019041113340591700_B2 article-title: Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005 publication-title: Cancer doi: 10.1002/cncr.24416 – ident: key 2019041113340591700_B27 – volume: 15 start-page: 2287 issue: 8 year: 2008 ident: key 2019041113340591700_B13 article-title: Incidental and nonincidental papillary thyroid microcarcinoma publication-title: Ann Surg Oncol doi: 10.1245/s10434-008-9958-2 – volume: 118 start-page: 2069 issue: 8 year: 2012 ident: key 2019041113340591700_B33 article-title: A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma publication-title: Cancer doi: 10.1002/cncr.26425 – volume: 167 start-page: 267 issue: 2 year: 2012 ident: key 2019041113340591700_B31 article-title: Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma publication-title: Eur J Endocrinol doi: 10.1530/EJE-12-0105 – volume: 21 start-page: 1559 issue: 11 year: 2002 ident: key 2019041113340591700_B25 article-title: How should meta-regression analyses be undertaken and interpreted? publication-title: Stat Med doi: 10.1002/sim.1187 – volume: 89 start-page: 3713 issue: 8 year: 2004 ident: key 2019041113340591700_B15 article-title: Clinical Behavior and Outcome of Papillary Thyroid Cancers Smaller than 1.5 cm in Diameter: Study of 299 Cases publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2003-031982 – start-page: 9 year: 1988 ident: key 2019041113340591700_B1 article-title: Histologic types of thyroid tumours in World Health Organisation histological classification of tumors – volume: 53 start-page: 23 issue: 1 year: 2007 ident: key 2019041113340591700_B45 article-title: Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably benign thyroid disease publication-title: J Postgrad Med doi: 10.4103/0022-3859.30323 – volume: 95 start-page: 555 issue: 7 year: 2007 ident: key 2019041113340591700_B26 article-title: Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience publication-title: J Surg Oncol doi: 10.1002/jso.20746 – volume: 46 start-page: 209 issue: 1 year: 1999 ident: key 2019041113340591700_B8 article-title: Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors publication-title: Endocr J doi: 10.1507/endocrj.46.209 – volume: 65 start-page: 1173 issue: 5 year: 1990 ident: key 2019041113340591700_B35 article-title: Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases publication-title: Cancer doi: 10.1002/1097-0142(19900301)65:5<1173::AID-CNCR2820650524>3.0.CO;2-2 – volume: 91 start-page: 2171 issue: 6 year: 2006 ident: key 2019041113340591700_B38 article-title: Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2005-2372 – volume: 254 start-page: 653 year: 2011 ident: key 2019041113340591700_B23 article-title: Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases publication-title: Ann Surg doi: 10.1097/SLA.0b013e318230036d – volume: 30 start-page: 759 issue: 5 year: 2006 ident: key 2019041113340591700_B7 article-title: Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? publication-title: World J Surg doi: 10.1007/s00268-005-0363-8 – ident: key 2019041113340591700_B20 – volume: 97 start-page: 1250 issue: 4 year: 2012 ident: key 2019041113340591700_B24 article-title: Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2011-1546 – volume: 52 start-page: 128 issue: 1 year: 2013 ident: key 2019041113340591700_B29 article-title: High level of distress in long-term survivors of thyroid carcinoma: Results of rapid screening using the distress thermometer publication-title: Acta Oncol doi: 10.3109/0284186X.2012.723822 – volume: 34 start-page: 1222 issue: 6 year: 2010 ident: key 2019041113340591700_B17 article-title: Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes publication-title: World J Surg doi: 10.1007/s00268-009-0359-x – volume: 33 start-page: 696 issue: 5 year: 2011 ident: key 2019041113340591700_B30 article-title: Classification of papillary thyroid microcarcinoma according to size and fine-needle aspiration cytology: Behavior and therapeutic implications publication-title: Head Neck doi: 10.1002/hed.21517 – volume: 16 start-page: 920 issue: 4 year: 2009 ident: key 2019041113340591700_B41 article-title: Extent of thyroidectomy and lymphadenectomy in 254 patients with papillary thyroid microcarcinoma: a single-institution experience publication-title: Ann Surg Oncol doi: 10.1245/s10434-009-0332-9 – volume: 19 start-page: 473 issue: 5 year: 2009 ident: key 2019041113340591700_B16 article-title: Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? publication-title: Thyroid doi: 10.1089/thy.2008.0185 – volume: 34 start-page: 28 issue: 1 year: 2010 ident: key 2019041113340591700_B36 article-title: An observational trial for papillary thyroid microcarcinoma in Japanese patients publication-title: World J Surg doi: 10.1007/s00268-009-0303-0 – volume: 76 start-page: 306 issue: 3 year: 2010 ident: key 2019041113340591700_B47 article-title: Are papillary microcarcinomas of the thyroid gland revealed by cervical adenopathy more aggressive? publication-title: Am Surg doi: 10.1177/000313481007600313 – volume: 43 start-page: 13 issue: Pt 1 year: 2006 ident: key 2019041113340591700_B19 article-title: Excellence NIfHaC, Biochemistry CSRCotAfC. National Institute for Health and Clinical Excellence guidelines on preoperative tests: the use of routine preoperative tests for elective surgery publication-title: Ann Clin Biochem doi: 10.1258/000456306775141623 – volume: 237 start-page: 399 issue: 3 year: 2003 ident: key 2019041113340591700_B37 article-title: Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection publication-title: Ann Surg doi: 10.1097/01.SLA.0000055273.58908.19 – volume: 46 start-page: 115 issue: 4 year: 2007 ident: key 2019041113340591700_B39 article-title: Papillary microcarcinoma and papillary cancer of the thyroid <or = 1 cm: modified definition of the WHO and the therapeutic dilemma publication-title: Nuklearmedizin doi: 10.1160/nukmed-0059 – volume: 18 start-page: 1916 issue: 7 year: 2011 ident: key 2019041113340591700_B48 article-title: Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma: is it a real prognostic factor? publication-title: Ann Surg Oncol doi: 10.1245/s10434-011-1556-z – volume: 237 start-page: 794 issue: 3 year: 2005 ident: key 2019041113340591700_B5 article-title: Management of thyroid nodules detected at US: society of radiologists in ultrasound consensus conference statement publication-title: Radiology doi: 10.1148/radiol.2373050220 – volume: 35 start-page: 118 issue: 2 year: 2010 ident: key 2019041113340591700_B9 article-title: Treatment and prognostic factors of papillary thyroid microcarcinoma publication-title: Clin Otolaryngol doi: 10.1111/j.1749-4486.2010.02085.x – volume: 24 start-page: 231 issue: 2 year: 2005 ident: key 2019041113340591700_B14 article-title: High risk for microcarcinoma in thyroid benign diseases. Incidence in a one year period of total thyroidectomies publication-title: J Exp Clin Cancer Res – volume: 33 start-page: 460 issue: 3 year: 2009 ident: key 2019041113340591700_B42 article-title: Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors publication-title: World J Surg doi: 10.1007/s00268-008-9870-8 – volume: 295 start-page: 2164 issue: 18 year: 2006 ident: key 2019041113340591700_B3 article-title: Increasing incidence of thyroid cancer in the United States, 1973–2002 publication-title: JAMA doi: 10.1001/jama.295.18.2164 – volume: 7 start-page: 177 issue: 3 year: 1986 ident: key 2019041113340591700_B21 article-title: Meta-analysis in clinical trials publication-title: Control Clin Trials doi: 10.1016/0197-2456(86)90046-2 – volume: 19 start-page: 707 issue: 7 year: 2009 ident: key 2019041113340591700_B22 article-title: Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients publication-title: Thyroid doi: 10.1089/thy.2008.0270 – volume: 87 start-page: 1810 issue: 4 year: 2002 ident: key 2019041113340591700_B32 article-title: Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.87.4.8352 – volume: 97 start-page: 1169 issue: 4 year: 2012 ident: key 2019041113340591700_B4 article-title: Management of papillary microcarcinoma: primum non nocere? publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-1465 – volume: 56 start-page: 531 issue: 3 year: 1985 ident: key 2019041113340591700_B34 article-title: Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study publication-title: Cancer doi: 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3 – volume: 31 start-page: 1672 issue: 8 year: 2007 ident: key 2019041113340591700_B12 article-title: Prognosis of patients with benign thyroid diseases accompanied by incidental papillary carcinoma undetectable on preoperative imaging tests publication-title: World J Surg doi: 10.1007/s00268-007-9131-2 – volume: 176 start-page: 1087 issue: 7 year: 1992 ident: key 2019041113340591700_B18 article-title: Is thyroid cancer a severe cancer? (Prognostic study of 800 surgically-treated cases of which 143 nodular differentiated cancers were followed-up for more than 20 years) publication-title: Bull Acad Natl Med – volume: 13 start-page: 47 issue: 3 year: 2009 ident: key 2019041113340591700_B10 article-title: Comparison of Papillary Thyroid Microcarcinoma and Carcinoma publication-title: Turk J Endocrinol Metab – volume: 26 start-page: 3 issue: 1 year: 2005 ident: key 2019041113340591700_B44 article-title: Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough? publication-title: Nucl Med Commun doi: 10.1097/00006231-200501000-00002 – volume: 34 start-page: 1214 issue: 6 year: 2010 ident: key 2019041113340591700_B11 article-title: Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area publication-title: World J Surg doi: 10.1007/s00268-009-0375-x – volume: 393 start-page: 25 issue: 1 year: 2008 ident: key 2019041113340591700_B46 article-title: Incidental papillary microcarcinoma of the thyroid–factors affecting lymph node metastasis publication-title: Langenbecks Arch Surg doi: 10.1007/s00423-007-0213-2 |
SSID | ssj0014453 |
Score | 2.516509 |
SecondaryResourceType | review_article |
Snippet | Context:There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring... CONTEXT:There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring... There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different... |
SourceID | proquest pubmed pascalfrancis crossref wolterskluwer oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2834 |
SubjectTerms | Adult Biological and medical sciences Carcinoma, Papillary - diagnosis Carcinoma, Papillary - mortality Carcinoma, Papillary - therapy Data collection Endocrinopathies Feeding. Feeding behavior Female Follow-Up Studies Fundamental and applied biological sciences. Psychology Humans Incidental Findings Lymph nodes Male Malignant tumors Medical sciences Meta-analysis Middle Aged Papillary thyroid cancer Prognosis Recurrence Risk Factors Survival Analysis Thyroid gland Thyroid Neoplasms - diagnosis Thyroid Neoplasms - mortality Thyroid Neoplasms - therapy Thyroid. Thyroid axis (diseases) Tumors Vertebrates: anatomy and physiology, studies on body, several organs or systems Vertebrates: endocrinology |
Title | Differences in the Recurrence and Mortality Outcomes Rates of Incidental and Nonincidental Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis of 21 329 Person-Years of Follow-up |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201408000-00030 https://www.ncbi.nlm.nih.gov/pubmed/24828487 https://www.proquest.com/docview/3164472048 https://www.proquest.com/docview/1552375876 |
Volume | 99 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tb9MwELa2ISEkQLwNCmMyEnyajOIkTRy-FWip0F7Q6KTyKXLiVNtok9KmmsYP5HdxZzsvFdsEfIlS52pHusc-n3P3HCGvva6T-ZPMZ8r1EuaHkjMh_S7jylO-4FwJHTx-cBgMT_zP4-54Y_NeK2ppVSZv059X5pX8j1ahDfSKWbL_oNm6U2iAe9AvXEHDcP0rHX-01U1MVJXeQx7j-blhjtUhFHp3jTvto1UJrwCCx7i7NBkkKVYULS1bwCEezNYtX-Qc6xEtLvdGp5eL4kxhgD0YOyw9lBczaTLavzY80JahXw-alZK12U5cvue5kY62L3L2DSaXbh4ABosLZs--zhvctugs6szNLFcFrHB5wxk1g2GSYlpxIGoW4VOZmyS3IVaVrh_0pmwmf2AcsMYnGMWk-fiysLVJ3jdZcQ25Qn9mDZc9GeF-HZdX3pRx2bYGGJ4S6nLuYAuNAYgAqCE3McOVhTAlnOxMEO3lvjqJzexPQzn1h1kCvxrNElJmco-Bzy0a81uFHBwexYOT_f141B-PNsktNwx12MGncR2yBL6vZVW1720TOTALq9332hbLpG3encsl6GpiirVc5U2BzEWBARrL7zo_o7XLGj0g9617RHsG6w_JRpY_IrcPbADIY_KrBXl6llOAPG0gTwEWtIY8rSBPNeRpMaEN5LXoGuRpDXlqIU_XIf-O9mgDeGoAb4ZsAx7HcTkFwNM24LG5BvwTcjLojz4MmS1FwlI_ch02AbdJJZFIVZA5fqI4aIdn3UAFUk3ASUm5I8MgiDxPBOASKTeUKgl5EqRcCqUcb5ts5UWePSM0DUBfXQG98tRPHRk5IpCph99OOHo_HbJXaS9OLU8_louZxuivw3_j8zRGXceo6w55U0vPDT_NNXIUgHCdCDMiu2soqYVdEYGdDkFgp4JNbBeCZexx8Kiw0hU8flU_BhuFHx5lnhWrZYw0j17YhY1Xhzw1cGs69wVMGxF2CFvDX2zywGN9iAGDM5zh6N5qIgzPeX7zy7wgd5olYYdslYtV9hLchzLZ1XPqN_R1HK0 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differences+in+the+Recurrence+and+Mortality+Outcomes+Rates+of+Incidental+and+Nonincidental+Papillary+Thyroid+Microcarcinoma%3A+A+Systematic+Review+and+Meta-Analysis+of+21+329+Person-Years+of+Follow-up&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Mehanna%2C+Hisham&rft.au=Al-maqbili%2C+Taleb&rft.au=Carter%2C+Ben&rft.au=Martin%2C+Emma&rft.date=2014-08-01&rft.pub=Oxford+University+Press&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=99&rft.issue=8&rft.spage=2834&rft.epage=2843&rft_id=info:doi/10.1210%2Fjc.2013-2118&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |